Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs. 2010

Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Dennis Pak, and Rong He, and Scott G Franzblau
Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, IL 60612, United States.

5-(2,8-Bis(trifluoromethyl)quinolin-4-yloxymethyl)isoxazole-3-carboxylic acid ethyl ester (compound 3) was reported to have excellent antituberculosis activity against both replicating and non-replicating Mycobacterium tuberculosis, with a minimum inhibitory concentration (MIC) of 0.9 microM and 12.2 microM, respectively. In this study, the antituberculosis activity of compound 3 was further investigated. Its activity appeared to be very specific for organisms of the M. tuberculosis complex and it effected significant reductions of bacterial numbers in infected macrophages with an EC(90) of 4.1 microM. More importantly, the increased in vitro antituberculosis activity of the corresponding acid (compound 4) at pH 6.0 suggested that it may be active in vivo in an acidic environment produced as a consequence of inflammation in the lungs of TB patients. The fact that various ester bioisosteres of compound 3 lost anti-TB activity further suggested that the ester compound 3 may function as a prodrug. The detailed structure-activity relationships (SARs) from this study should facilitate our ultimate goal of improving the anti-TB potency of this isoxazole ester series.

UI MeSH Term Description Entries
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D002264 Carboxylic Acids Organic compounds containing the carboxy group (-COOH). This group of compounds includes amino acids and fatty acids. Carboxylic acids can be saturated, unsaturated, or aromatic. Carboxylic Acid,Acid, Carboxylic,Acids, Carboxylic
D004952 Esters Compounds derived from organic or inorganic acids in which at least one hydroxyl group is replaced by an –O-alkyl or another organic group. They can be represented by the structure formula RCOOR’ and are usually formed by the reaction between an acid and an alcohol with elimination of water. Ester
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D015767 Mefloquine A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects. Lariam,Mefloquine Hydrochloride,Mephloquine,Ro-21-5998-001,WR-142,490,WR-177,602,Ro 21 5998 001,Ro215998001,WR 142,490,WR 177,602,WR142,490,WR177,602

Related Publications

Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Dennis Pak, and Rong He, and Scott G Franzblau
November 2007, ChemMedChem,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Dennis Pak, and Rong He, and Scott G Franzblau
February 2010, Archiv der Pharmazie,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Dennis Pak, and Rong He, and Scott G Franzblau
April 1988, Journal of pharmaceutical sciences,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Dennis Pak, and Rong He, and Scott G Franzblau
March 2002, Bioorganic & medicinal chemistry,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Dennis Pak, and Rong He, and Scott G Franzblau
May 2009, Bioorganic & medicinal chemistry letters,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Dennis Pak, and Rong He, and Scott G Franzblau
June 2006, ChemMedChem,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Dennis Pak, and Rong He, and Scott G Franzblau
December 2019, The Journal of organic chemistry,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Dennis Pak, and Rong He, and Scott G Franzblau
January 1992, Arzneimittel-Forschung,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Dennis Pak, and Rong He, and Scott G Franzblau
May 2005, Bioorganic & medicinal chemistry letters,
Jialin Mao, and Hai Yuan, and Yuehong Wang, and Baojie Wan, and Dennis Pak, and Rong He, and Scott G Franzblau
January 1991, Acta pharmaceutica Nordica,
Copied contents to your clipboard!